When creatine first came up in conversations about menopause, the reaction was almost universally the same: 'Isn't that what teenage boys take to bulk up?' The assumption that it had nothing to offer women over 45 kept so many from even looking at the research — and the research, it turns out, is quietly compelling. This one felt worth digging into properly.
Learn more about Rose →Oestrogen plays a significant role in maintaining satellite cell activity and reducing protein degradation in skeletal muscle, so its decline at menopause creates a physiological environment that actively favours muscle loss. Creatine increases phosphocreatine stores in muscle tissue, which enhances the capacity to regenerate ATP rapidly during contraction — the exact energy currency muscle needs to grow and repair. This mechanism means creatine supplementation addresses one of the downstream consequences of oestrogen withdrawal at a cellular level, not just a surface one.
A 2021 systematic review and meta-analysis published in Nutrients analysed trials specifically in older adults and found that creatine supplementation combined with resistance training produced significantly greater increases in lean mass and upper and lower body strength compared to resistance training with placebo. The effect sizes were modest but clinically relevant — particularly for a population where preserving even small amounts of lean mass has outsized effects on metabolic health and fall risk. Resistance training remains non-negotiable, but creatine appears to make that training work harder.
A landmark randomised controlled trial by Chilibeck and colleagues followed postmenopausal women supplementing with creatine alongside resistance training for one year and found that the creatine group lost significantly less bone mineral density at the femoral neck compared to placebo. The proposed mechanism involves creatine's role in supporting osteoblast energy metabolism and its indirect effects on IGF-1 signalling, both of which influence bone formation. Bone density loss accelerates sharply in the years immediately following menopause, making this a window where any evidence-backed intervention warrants genuine consideration.
Neuroimaging research has documented reduced cerebral glucose metabolism in perimenopausal and early postmenopausal women, a pattern associated with cognitive complaints including brain fog, word-finding difficulties, and reduced processing speed. Creatine plays a central role in the phosphocreatine energy buffer system in neurons, helping maintain ATP availability during periods of high demand or reduced glucose uptake. Supplementing creatine has been shown in several trials to increase brain creatine concentrations, which is biologically plausible as a mechanism for supporting cognitive resilience during the menopause transition.
A 2023 meta-analysis in Nutritional Neuroscience pooled data from randomised trials and found that creatine supplementation produced significant improvements in memory tasks — particularly short-term and working memory — in adults over 60, with larger effects seen in those over 70. The trials were not exclusively in menopausal women, but the age overlap is substantial and the neurological mechanisms are not sex-specific at the basic level. This positions creatine as one of the few affordable, well-tolerated compounds with actual trial data behind cognitive claims rather than marketing copy.
Research from the University of Sydney demonstrated that creatine supplementation attenuated the cognitive decline associated with sleep deprivation, with participants maintaining better performance on tasks requiring complex reasoning and working memory after a night of disrupted sleep. Given that sleep disruption is one of the most prevalent and debilitating symptoms of perimenopause, this is a particularly relevant finding — it suggests creatine may provide a modest protective effect on cognitive function during the nights and days that follow poor sleep. This area of research is still early but the mechanistic logic is sound: creatine helps neurons maintain energy homeostasis under metabolic stress.
Multiple small randomised trials have found that creatine supplementation — particularly in women — augments the effects of antidepressant medication and may have independent mood-stabilising effects, potentially through its influence on brain bioenergetics and serotonin metabolism. A 2012 trial published in the American Journal of Psychiatry found that women with major depressive disorder who added creatine to their SSRI regimen showed significantly faster and greater symptom improvement than placebo. Depression and low mood are substantially more common in perimenopause and the early postmenopause years, making any intervention with biological plausibility and a reasonable safety profile worth knowing about.
Creatine monohydrate has been studied in thousands of trials over more than three decades, across populations ranging from elite athletes to older adults with neurodegenerative disease, and no serious adverse effects have been identified at standard doses in people with healthy kidneys. The persistent myths about kidney damage have been repeatedly examined and not supported by controlled research in otherwise healthy individuals — the concern originated from case reports in people who already had pre-existing kidney conditions. For women who are supplement-cautious or who have been burned by wellness industry overclaiming, creatine's safety profile stands as genuinely unusual in how well it is characterised.
Creatine is found almost exclusively in animal muscle tissue — red meat and fish are the richest sources — and many women in midlife reduce their consumption of these foods for various reasons including cardiovascular health concerns, digestive changes, or dietary preference shifts. The body synthesises creatine endogenously from amino acids, but this production declines with age and may not compensate for reduced dietary intake, leaving muscle and brain creatine stores lower than optimal. For women eating plant-forward or reduced-meat diets, the case for considering creatine supplementation becomes particularly compelling given that this group has essentially no dietary creatine intake at baseline.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.